BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...Phase Ib trial of the same combination in EBV-positive solid tumors, including gastric and nasopharyngeal cancers.Shenzhen Salubris Pharmaceuticals Co. Ltd....
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...Co. Ltd (SZSE:002020) was up RMB0.26 to RMB8.88; and Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino...
BioCentury | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San...
...about $16.5 million to date. Slack said the round would close no later than 1Q19. Salubris...
...“Viral Vulnerability” ). Viracta Therapeutics Inc., San Diego, Calif. Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294), Guangdong, China Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta...
BioCentury | Dec 4, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San...
...about $16.5 million to date. Slack said the round would close no later than 1Q19. Salubris...
...proteins that make cancerous cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta...
BioCentury | Sep 29, 2017
Financial News

Go gets $5M from Salubris

...On Sept. 25, the Salubris Pharmaceutical Ltd. subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) invested $5 million in cancer...
...cancer company Go Therapeutics Inc. (Cambridge, Mass.). Go Therapeutics Inc. , Cambridge, Mass. Chris Lieu Go Therapeutics Inc. Shenzhen Salubris Pharmaceuticals Co. ltd....
Items per page:
1 - 5 of 5
BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...Phase Ib trial of the same combination in EBV-positive solid tumors, including gastric and nasopharyngeal cancers.Shenzhen Salubris Pharmaceuticals Co. Ltd....
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...Co. Ltd (SZSE:002020) was up RMB0.26 to RMB8.88; and Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino...
BioCentury | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San...
...about $16.5 million to date. Slack said the round would close no later than 1Q19. Salubris...
...“Viral Vulnerability” ). Viracta Therapeutics Inc., San Diego, Calif. Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294), Guangdong, China Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta...
BioCentury | Dec 4, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San...
...about $16.5 million to date. Slack said the round would close no later than 1Q19. Salubris...
...proteins that make cancerous cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta...
BioCentury | Sep 29, 2017
Financial News

Go gets $5M from Salubris

...On Sept. 25, the Salubris Pharmaceutical Ltd. subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) invested $5 million in cancer...
...cancer company Go Therapeutics Inc. (Cambridge, Mass.). Go Therapeutics Inc. , Cambridge, Mass. Chris Lieu Go Therapeutics Inc. Shenzhen Salubris Pharmaceuticals Co. ltd....
Items per page:
1 - 5 of 5